Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 5 minute read General business news Crest Nicholson (LSE: CRST) posts FY25 profit growth as mid-premium strategy begins to take hold Crest Nicholson is narrowing its focus to mid-premium homes. Find out how FY25 results reflect this pivot—and what could define FY26 success. bySrinathJanuary 31, 2026